Drugs / TST003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05731271 | Feb 2023 → Jun 2026 overdue | colorectal adenocarcinoma, metastatic neoplasm | Suzhou Transcenta Therapeutics Co., Ltd. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2024-04-10 | Suzhou Transcenta Therapeutics Co., Ltd. | Results Transcenta Presents Osemitamab (TST001) and TST003 Study Results at AACR 2024 transcenta.com ↗ |
| 2023-04-18 | Suzhou Transcenta Therapeutics Co., Ltd. | Results Transcenta Presents Two Preclinical Studies at AACR 2023 transcenta.com ↗
Preclinical characterization results provided the rationale for on-going clinical evaluation of TST003 in patients with advanced solid tumors with high unmet medical need eithe |
| 2023-01-04 | Suzhou Transcenta Therapeutics Co., Ltd. | Regulatory Transcenta Received IND Clearance from NMPA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors transcenta.com ↗ |
| 2022-09-14 | Suzhou Transcenta Therapeutics Co., Ltd. | Regulatory Transcenta Received IND Clearance from FDA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors transcenta.com ↗
TST003, its first-in-class, high affinity humanized monoclonal antibody targeting Gremlin1, has received IND clearance from U.S. Food and Drug Administration (FDA). |
| 2022-05-30 | Suzhou Transcenta Therapeutics Co., Ltd. | Results Nature Cancer Publishes the Study Results by Transcenta and Shanghai Jiao Tong University Scientists on the Potential Application of Transcenta’s First-In-Class Gremlin1 Targeting Antibody in the Treatment of Androgen Receptor-Negative/Low Prostate Cancer transcenta.com ↗
Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that Nature Cancer, an international authoritative journal in oncology field, publishes the results of preclinical studies of Transcenta’s first-in-class Gremlin1 targeting antibody (TST003) in the treatment of castration resistant prostate cancer. |
All press releases naming this drug 6 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TST003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05731271 ↗ |
| Modality | Monoclonal antibody | “IV humanized anti-GREM1 monoclonal antibody” NCT05731271 ↗ |
| Route | Intravenous | “TST003 intravenously (through a needle into your vein)” NCT05731271 ↗ |
| Target | GREM1 | “anti-GREM1 monoclonal antibody” NCT05731271 ↗ |